RANBP2 and prostate carcinoma: Three variants found in our lymphoid neoplasm-specific analysis had increased frequencies in cases who also had a diagnosis of prostate cancer: rs535484207 (RANBP2, OR [95% CI] = 256.01 [26.82, 2442.95], p = 1.46 × 10−6), rs139586367 (UFL1, OR [95% CI] = 284.06 [27.95, 2886.15], p = 1.79 × 10−6), and rs191064896 (ADGRB1, OR [95% CI] = 108.36 [15.02, 781.08], p = 3.32 × 10−6), where 21.4%, 40.0%, and 25.0% of carriers for the risk-increasing allele, for each respective variant, had both cancers.